AIDS Vaccine's Low Efficacy Rate Makes Cmte. Skeptical About Phase III Potential
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA committee members express concern over vaccine's low CD8 cytotoxic T lymphocyte activity and lack of neutralizing antibody response in Phase II trial. Agency cites regulatory challenge associated with approving a vaccine that is not effective against U.S. sub-type of AIDS virus.